Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 25017001)

1.

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.

Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P.

Am J Psychiatry. 2014 Dec 1;171(12):1278-86. doi: 10.1176/appi.ajp.2014.14010094. Epub 2014 Oct 31.

PMID:
25017001
2.

Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression.

Dunlop BW, Kelley ME, McGrath CL, Craighead WE, Mayberg HS.

J Neuropsychiatry Clin Neurosci. 2015 Jun 12:appineuropsych14030048. [Epub ahead of print]

PMID:
26067435
3.

Target-based biomarker selection - Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression.

Büttner M, Jezova D, Greene B, Konrad C, Kircher T, Murck H.

J Psychiatr Res. 2015 Jul-Aug;66-67:24-37. doi: 10.1016/j.jpsychires.2015.04.012. Epub 2015 Apr 23.

PMID:
25959615
4.

Exploring the role of drug-metabolising enzymes in antidepressant side effects.

Hodgson K, Tansey KE, Uher R, Dernovšek MZ, Mors O, Hauser J, Souery D, Maier W, Henigsberg N, Rietschel M, Placentino A, Craig IW, Aitchison KJ, Farmer AE, Dobson RJ, McGuffin P.

Psychopharmacology (Berl). 2015 Jul;232(14):2609-17. doi: 10.1007/s00213-015-3898-x. Epub 2015 Mar 12.

5.

A new role for nortriptyline in depression associated with vascular disease?

Kunte H, Rentzsch J, Kronenberg G.

Am J Psychiatry. 2015 Feb 1;172(2):201. doi: 10.1176/appi.ajp.2014.14070926. No abstract available.

PMID:
25640936
6.

Response to Kunte et al.

Uher R.

Am J Psychiatry. 2015 Feb 1;172(2):201. doi: 10.1176/appi.ajp.2014.14070926r. No abstract available.

PMID:
25640935
7.

Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?

Gerra ML, Marchesi C, Amat JA, Blier P, Hellerstein DJ, Stewart JW.

J Clin Psychiatry. 2014 Sep;75(9):e939-44. doi: 10.4088/JCP.14m09025.

PMID:
25295437
8.

An electronic health records study of long-term weight gain following antidepressant use.

Blumenthal SR, Castro VM, Clements CC, Rosenfield HR, Murphy SN, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Smoller JW, Perlis RH.

JAMA Psychiatry. 2014 Aug;71(8):889-96. doi: 10.1001/jamapsychiatry.2014.414.

PMID:
24898363
9.

Baseline difference between patients' and clinicians' rated illness severity scores and subsequent outcomes in major depressive disorder: analysis of the sequenced treatment alternatives to relieve depression data.

Tada M, Uchida H, Suzuki T, Abe T, Pollock BG, Mimura M.

J Clin Psychopharmacol. 2014 Jun;34(3):297-302. doi: 10.1097/JCP.0000000000000112. No abstract available.

10.

Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting.

Dolberg O, Larsson Lönn S, Kvist K.

Curr Med Res Opin. 2014 Jul;30(7):1301-7. doi: 10.1185/03007995.2014.904770. Epub 2014 Mar 27.

PMID:
24628498
11.

DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP.

Powell TR, Smith RG, Hackinger S, Schalkwyk LC, Uher R, McGuffin P, Mill J, Tansey KE.

Transl Psychiatry. 2013 Sep 3;3:e300. doi: 10.1038/tp.2013.73.

12.

Toward a neuroimaging treatment selection biomarker for major depressive disorder.

McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS.

JAMA Psychiatry. 2013 Aug;70(8):821-9. doi: 10.1001/jamapsychiatry.2013.143.

13.

Self-report and clinician-rated measures of depression severity: can one replace the other?

Uher R, Perlis RH, Placentino A, Dernovšek MZ, Henigsberg N, Mors O, Maier W, McGuffin P, Farmer A.

Depress Anxiety. 2012 Dec;29(12):1043-9. doi: 10.1002/da.21993. Epub 2012 Aug 29.

14.

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T.

Ann Intern Med. 2012 Jul 17;157(2):94-103. doi: 10.7326/0003-4819-157-2-201207170-00006.

PMID:
22801672
15.

Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder.

Power RA, Muthén B, Henigsberg N, Mors O, Placentino A, Mendlewicz J, Maier W, McGuffin P, Lewis CM, Uher R.

J Psychiatr Res. 2012 Oct;46(10):1333-8. doi: 10.1016/j.jpsychires.2012.06.014. Epub 2012 Jul 6.

PMID:
22770672
16.

Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.

Bose A, Tsai J, Li D.

Clin Drug Investig. 2012 Jun 1;32(6):373-85. doi: 10.2165/11631890-000000000-00000.

PMID:
22559255
17.

Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.

Raskin J, George T, Granger RE, Hussain N, Zhao GW, Marangell LB.

J Psychiatr Res. 2012 May;46(5):667-74. doi: 10.1016/j.jpsychires.2012.02.010. Epub 2012 Mar 10.

PMID:
22410206
18.

Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder.

Uher R, Carver S, Power RA, Mors O, Maier W, Rietschel M, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Placentino A, Farmer A, McGuffin P.

Psychol Med. 2012 Oct;42(10):2027-35. doi: 10.1017/S0033291712000190. Epub 2012 Mar 6.

PMID:
22391106
19.

[Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].

Favré P.

Encephale. 2012 Feb;38(1):86-96. doi: 10.1016/j.encep.2011.11.003. Epub 2011 Dec 10. Review. French.

PMID:
22381728
20.

Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.

Uher R, Mors O, Rietschel M, Rajewska-Rager A, Petrovic A, Zobel A, Henigsberg N, Mendlewicz J, Aitchison KJ, Farmer A, McGuffin P.

J Clin Psychiatry. 2011 Nov;72(11):1478-84. doi: 10.4088/JCP.10m06419.

PMID:
22127194
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk